Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling.

Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling. Abstract Text:

    yu wangYu Wang,qiu zhaoQiu Zhao,songlin maSonglin Ma,fang yangFang Yang,yong gongYong Gong,changshu keChangshu Ke,yu wangYu Wang,qiu zhaoQiu Zhao,songlin maSonglin Ma,fang yangFang Yang,yong gongYong Gong,changshu keChangshu Ke,yu wangYu Wang,qiu zhaoQiu Zhao,songlin maSonglin Ma,fang yangFang Yang,yong gongYong Gong,changshu keChangshu Ke,

    Sirolimus(SRL, Rapamune(â), rapamycin) is a highly specific inhibitor of mammalian target of rapamycin (mTOR). Sirolimus exerts its biological activity by inhibiting the serine-threonine kinase mammalian target of rapamycin (mTOR), which regulates important cellular processes such as control of cell cycle, cell size, translation initiation and transcription. The ability of sirolimus to inhibit cancer cell proliferation has led to efforts to develop rapamycin and related mTOR inhibitors as anticancer agents. Here, we made mTOR as a controlling target, using a new immunosuppressant named sirolimus, to investigate the inhibitory effects of sirolimus on cell proliferation and the expression of mTOR, Hypoxia-inducible factor-1 alpha(HIF-1alpha) and vascular endothelial growth factor (VEGF) in human pancreatic carcinoma SW1990 cell line. Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway. Thus, the targeting of mTOR signaling has been exploited as a novel therapy for human cancers. iubmb Life, 59: 717-721, 2007.

    Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling. Publishing Authors By Initials

    y wangY Wang,q zhaoQ Zhao,s maS Ma,f yangF Yang,y gongY Gong,c keC Ke,y wangY Wang,q zhaoQ Zhao,s maS Ma,f yangF Yang,y gongY Gong,c keC Ke,y wangY Wang,q zhaoQ Zhao,s maS Ma,f yangF Yang,y gongY Gong,c keC Ke,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: IUBMB life

    VOLUME: 59

    Page Numbers: 717-21

    Journal Abbreviation: IUBMB Life

    ISSN: 1521-6543

    DAY: 30

    MONTH: Nov

    YEAR: 2007

    Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 100888706

    Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling.

    AFFILIATION: Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: IUBMB Life

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by a Mechanism Linked to the Targeting of mTOR/HIF-1 Alpha/VEGF Signaling Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News